Skip to main content
. 2017 Feb 10;8:53. doi: 10.3389/fphar.2017.00053

FIGURE 2.

FIGURE 2

Systemic (A) 4-HNE and (B) H2O2 levels in patients with RA treated or not with either leflunomide (LFN; n = 15) or adalimumab (ADA; n = 15), in comparison with patients recently diagnosed with RA but not yet receiving specific treatment with anti-rheumatic drugs (NST group; n = 10) and healthy subjects (n = 15). Data are expressed as mean ± SD. p < 0.05, differs from healthy subjects; #p < 0.05, differs from the NST group.